Kanta Subbarao
#99,409
Most Influential Person Now
Indian virologist and physician
Kanta Subbarao's AcademicInfluence.com Rankings
Kanta Subbaraophilosophy Degrees
Philosophy
#5137
World Rank
#7866
Historical Rank
Logic
#2465
World Rank
#3460
Historical Rank
Kanta Subbaraobiology Degrees
Biology
#6550
World Rank
#9289
Historical Rank
Virology
#144
World Rank
#149
Historical Rank
Microbiology
#296
World Rank
#342
Historical Rank
Download Badge
Philosophy Biology
Kanta Subbarao's Degrees
- PhD Virology University of Oxford
Why Is Kanta Subbarao Influential?
(Suggest an Edit or Addition)According to Wikipedia, Kanta Subbarao is an Indian virologist, molecular geneticist, and physician-scientist. She is director of the World Health Organization collaborating centre for reference and research on influenza. Subbarao is also a professor at the Doherty Institute.
Kanta Subbarao's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection (2021) (2394)
- Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. (1998) (1404)
- Global epidemiology of influenza: past and present. (2000) (833)
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus (2004) (698)
- Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. (1999) (690)
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice (2004) (684)
- Systems biology of vaccination for seasonal influenza in humans (2011) (669)
- Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. (2000) (618)
- Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV (2004) (593)
- Predicting the evolution of human influenza A. (1999) (518)
- pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN (2004) (481)
- Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. (2010) (453)
- Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. (2004) (421)
- Adaptation to natural facial categories (420)
- A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice (2007) (413)
- Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice (2004) (412)
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection (2011) (404)
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection (2011) (386)
- Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. (2004) (372)
- A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo (2006) (363)
- Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 (2020) (350)
- Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection (2009) (345)
- Influenza (2017) (344)
- Lack of transmission of H5N1 avian–human reassortant influenza viruses in a ferret model (2006) (340)
- Mechanisms of Host Defense following Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) Pulmonary Infection of Mice (2004) (323)
- Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets (2006) (281)
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies (2007) (281)
- Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS (2004) (275)
- Evaluation of candidate vaccine approaches for MERS-CoV (2015) (275)
- Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 (2021) (273)
- Scientific barriers to developing vaccines against avian influenza viruses (2007) (265)
- Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. (2003) (264)
- Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters (2005) (263)
- The Immunobiology of SARS*. (2007) (262)
- Identification and Characterization of Severe Acute Respiratory Syndrome Coronavirus Replicase Proteins (2004) (259)
- SARS-CoV-2 Variants and Vaccines (2021) (247)
- Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977-1999: evidence for wholly human and reassortant virus genotypes. (2000) (245)
- Influenza vaccines: challenges and solutions. (2015) (241)
- Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses (2016) (241)
- Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses (2017) (229)
- Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza (2007) (221)
- Neuraminidase Stalk Length and Additional Glycosylation of the Hemagglutinin Influence the Virulence of Influenza H5N1 Viruses for Mice (2009) (220)
- Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro (2006) (216)
- Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. (2016) (214)
- Glycosylation at 158N of the Hemagglutinin Protein and Receptor Binding Specificity Synergistically Affect the Antigenicity and Immunogenicity of a Live Attenuated H5N1 A/Vietnam/1203/2004 Vaccine Virus in Ferrets (2010) (208)
- Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys (2004) (204)
- Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans (2005) (200)
- The PB2 Subunit of the Influenza Virus RNA Polymerase Affects Virulence by Interacting with the Mitochondrial Antiviral Signaling Protein and Inhibiting Expression of Beta Interferon (2010) (196)
- Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 (2020) (190)
- Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine. (2018) (185)
- Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets (2009) (179)
- Respiratory Virus Infections: Understanding COVID-19 (2020) (177)
- Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. (1999) (176)
- DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. (2002) (174)
- Eurasian-Origin Gene Segments Contribute to the Transmissibility, Aerosol Release, and Morphology of the 2009 Pandemic H1N1 Influenza Virus (2011) (169)
- Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. (2002) (165)
- Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine (2005) (160)
- Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. (2015) (159)
- Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice (2005) (159)
- Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants (2005) (157)
- Development of effective vaccines against pandemic influenza. (2006) (153)
- A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. (2013) (152)
- Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. (1997) (152)
- Animal models for SARS and MERS coronaviruses (2015) (152)
- Emerging Respiratory Viruses: Challenges and Vaccine Strategies (2006) (146)
- SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism (2010) (143)
- Animal models and vaccines for SARS-CoV infection (2007) (139)
- Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. (1999) (139)
- Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease (2011) (137)
- Vaccines for Pandemic Influenza (2006) (134)
- Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. (2007) (132)
- Molecular changes associated with the transmission of avian influenza a H5N1 and H9N2 viruses to humans * (2002) (131)
- The soft palate is an important site of adaptation for transmissible influenza viruses (2015) (125)
- Avian influenza viruses infecting humans (2000) (121)
- Influenza A Virus Assembly Intermediates Fuse in the Cytoplasm (2014) (119)
- A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian Hamsters (2008) (118)
- Live attenuated influenza vaccine. (2020) (114)
- Is there an ideal animal model for SARS? (2006) (114)
- Molecular Correlates of Influenza A H5N1 Virus Pathogenesis in Mice (2000) (111)
- Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. (2009) (110)
- Systems Biology of Seasonal Influenza Vaccination in Humans (2011) (110)
- Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein (2005) (110)
- Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines (2020) (101)
- Recurrent rhinovirus infections in a child with inherited MDA5 deficiency (2017) (101)
- Influenza vaccines: present and future. (1999) (101)
- The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death (2009) (100)
- Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets (2008) (100)
- Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters (2006) (97)
- Molecular correlates of influenza A H5N1 virus pathogenesis in mice. (2001) (96)
- Integrated immune dynamics define correlates of COVID-19 severity and antibody responses (2020) (96)
- FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. (2008) (95)
- The Ferret Model for Influenza (2009) (92)
- Evaluation of Replication and Pathogenicity of Avian Influenza A H7 Subtype Viruses in a Mouse Model (2007) (92)
- Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies (2013) (92)
- A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. (2009) (92)
- Immunohistochemical and in situ hybridization studies of influenza A virus infection in human lungs. (2000) (91)
- Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus (2015) (91)
- A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. (2014) (91)
- The Multibasic Cleavage Site of the Hemagglutinin of Highly Pathogenic A/Vietnam/1203/2004 (H5N1) Avian Influenza Virus Acts as a Virulence Factor in a Host-Specific Manner in Mammals (2011) (89)
- The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. (2011) (88)
- Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19 (2020) (88)
- Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways (2009) (86)
- Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice (2021) (86)
- Avian-to-human transmission of H 9 N 2 subtype influenza A viruses : Relationship between H 9 N 2 and H 5 N 1 human isolates (2000) (85)
- H5N1 vaccines in humans. (2013) (85)
- Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection (2016) (84)
- Reassortment and evolution of current human influenza A and B viruses. (2004) (83)
- BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection (2021) (83)
- Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. (2016) (83)
- SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. (2012) (82)
- Palmitylation of the influenza virus hemagglutinin (H3) is not essential for virus assembly or infectivity (1996) (79)
- Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018. (2020) (78)
- Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models (2020) (78)
- Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. (2000) (78)
- A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. (2008) (76)
- A Single-Amino-Acid Substitution in a Polymerase Protein of an H5N1 Influenza Virus Is Associated with Systemic Infection and Impaired T-Cell Activation in Mice (2009) (76)
- In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination (2017) (73)
- Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody (2017) (71)
- The Mouse Model for Influenza (2009) (70)
- H5N1 Viruses and Vaccines (2007) (69)
- Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice (2012) (69)
- Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. (2014) (68)
- B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination (2013) (68)
- Influenza A virus infection complicated by fatal myocarditis. (2000) (67)
- Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. (2003) (66)
- The prospects and challenges of universal vaccines for influenza. (2013) (65)
- Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. (2003) (65)
- Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine (2011) (63)
- Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. (2003) (63)
- A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. (2009) (62)
- Molecular aspects of avian influenza (H5N1) viruses isolated from humans (2000) (61)
- Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. (2007) (60)
- Innate and adaptive T cells in influenza disease (2018) (60)
- Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season. (2002) (59)
- Encephalitis associated with influenza B virus infection in 2 children and a review of the literature. (2003) (58)
- Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. (2016) (58)
- Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine. (2010) (57)
- Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets (2014) (56)
- Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium (2012) (55)
- Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and Ferrets (2008) (54)
- Genomic Analysis Reveals Age-Dependent Innate Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (2008) (54)
- The success of SARS-CoV-2 vaccines and challenges ahead (2021) (53)
- Induction of H7N9-Cross-Reactive Antibody-Dependent Cellular Cytotoxicity Antibodies by Human Seasonal Influenza A Viruses that are Directed Toward the Nucleoprotein (2016) (53)
- Influenza vaccines generated by reverse genetics. (2004) (53)
- A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. (2016) (52)
- Engineering H5N1 avian influenza viruses to study human adaptation (2012) (52)
- Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. (2011) (52)
- Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge (2015) (51)
- A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and Monkeys (2010) (51)
- Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center. (1996) (50)
- Lymphopenia Associated with Highly Virulent H5N1 Virus Infection Due to Plasmacytoid Dendritic Cell–Mediated Apoptosis of T Cells (2014) (50)
- Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques (2021) (50)
- Live attenuated and inactivated influenza vaccines in children. (2015) (49)
- Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting (2020) (49)
- Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments (2018) (47)
- SARS Vaccine Protective in Mice (2005) (47)
- Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. (2010) (45)
- Severity of Clinical Disease and Pathology in Ferrets Experimentally Infected with Influenza Viruses Is Influenced by Inoculum Volume (2014) (45)
- Performance of Rapid Tests for Detection of Avian Influenza A Virus Types H5N1 and H9N2 (2006) (45)
- Evaluation of Replication and Cross-Reactive Antibody Responses of H2 Subtype Influenza Viruses in Mice and Ferrets (2010) (44)
- Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody (2015) (44)
- High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. (2015) (43)
- What level of neutralising antibody protects from COVID-19? . (2021) (43)
- Effect of Priming with H1N1 Influenza Viruses of Variable Antigenic Distances on Challenge with 2009 Pandemic H1N1 Virus (2012) (42)
- Attacking the flu: Neutralizing antibodies may lead to 'universal' vaccine (2009) (42)
- Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9) (2015) (42)
- The Wilhelmine E. Key 1999 Invitational lecture. Predicting the evolution of human influenza A. (2000) (42)
- Comparison of Heterosubtypic Protection in Ferrets and Pigs Induced by a Single-Cycle Influenza Vaccine (2018) (42)
- Pause on avian flu transmission research. (2012) (41)
- Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. (2011) (41)
- Immune Responses to Avian Influenza Viruses (2019) (40)
- Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. (2010) (38)
- Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine (2022) (38)
- An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. (2011) (37)
- An open‐label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults (2012) (37)
- An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. (1997) (37)
- The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. (2012) (37)
- Transmission Studies Resume for Avian Flu (2013) (37)
- Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial (2021) (36)
- Can Immunity Induced by the Human Influenza Virus N1 Neuraminidase Provide Some Protection from Avian Influenza H5N1 Viruses? (2007) (36)
- Immune imprinting and SARS-CoV-2 vaccine design (2021) (36)
- Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-Term Sterilizing Immunity against Heterologous Challenge (2010) (36)
- Moving On Out: Transport and Packaging of Influenza Viral RNA into Virions. (2016) (35)
- Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines (2017) (35)
- The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses (2017) (35)
- In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice (2017) (34)
- A Simple Restriction Fragment Length Polymorphism-Based Strategy That Can Distinguish the Internal Genes of Human H1N1, H3N2, and H5N1 Influenza A Viruses (2000) (34)
- Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine (2016) (34)
- Epidemiology and control of human and animal influenza. (2006) (34)
- The Contribution of Systemic and Pulmonary Immune Effectors to Vaccine-Induced Protection from H5N1 Influenza Virus Infection (2012) (33)
- Avian influenza H7N9 viruses: a rare second warning (2017) (33)
- Cellular targets for influenza drugs (2010) (33)
- The Matrix Gene Segment Destabilizes the Acid and Thermal Stability of the Hemagglutinin of Pandemic Live Attenuated Influenza Virus Vaccines (2014) (32)
- Comparison of Seroconversion in Children and Adults With Mild COVID-19 (2022) (32)
- Vesicular Stomatitis Virus-Based H5N1 Avian Influenza Vaccines Induce Potent Cross-Clade Neutralizing Antibodies in Rhesus Macaques (2011) (32)
- The Magnitude of Local Immunity in the Lungs of Mice Induced by Live Attenuated Influenza Vaccines Is Determined by Local Viral Replication and Induction of Cytokines (2010) (32)
- An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice (2010) (32)
- Pause on Avian Flu Transmission Research (2012) (32)
- Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms (2014) (31)
- Live attenuated vaccines for pandemic influenza. (2009) (31)
- Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes (2018) (30)
- Animal Models for Sars (2006) (30)
- African Green Monkeys Recapitulate the Clinical Experience with Replication of Live Attenuated Pandemic Influenza Virus Vaccine Candidates (2014) (29)
- Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2 (2021) (28)
- Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses? (1995) (28)
- The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. (2009) (27)
- Mammalian Adaptation in the PB2 Gene of Avian H5N1 Influenza Virus (2013) (27)
- Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. (2007) (27)
- Strand-Specific Dual RNA Sequencing of Bronchial Epithelial Cells Infected with Influenza A/H3N2 Viruses Reveals Splicing of Gene Segment 6 and Novel Host-Virus Interactions (2018) (27)
- Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. (2010) (26)
- Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination (2015) (25)
- Replication and Immunogenicity of Swine, Equine, and Avian H3 Subtype Influenza Viruses in Mice and Ferrets (2013) (25)
- Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination. (2018) (25)
- Pathogenesis, Humoral Immune Responses, and Transmission between Cohoused Animals in a Ferret Model of Human Respiratory Syncytial Virus Infection (2017) (24)
- In Vivo Imaging of Influenza Virus Infection in Immunized Mice (2017) (24)
- H5N1 Vaccine-Specific B Cell Responses in Ferrets Primed with Live Attenuated Seasonal Influenza Vaccines (2009) (24)
- Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features (2021) (24)
- Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) (2006) (23)
- Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H 5 N 1 Influenza (2007) (23)
- Molecular epidemiology of influenza A(H3N2) virus reinfections. (2002) (23)
- DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial (2018) (22)
- The Ongoing Battle Against Influenza: The challenge of flu transmission (2012) (22)
- Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets. (2013) (21)
- BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial) (2021) (21)
- Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain (2021) (21)
- Predicting the efficacy of variant-modified COVID-19 vaccine boosters (2022) (21)
- A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 (2021) (21)
- Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay (2021) (20)
- Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020 (2022) (20)
- ANALYSIS OF ANTIBACTERIAL ACTIVITY OF CURCUMIN AGAINST ENTEROCOCCUS FECALIS (2017) (20)
- Evaluation of Three Live Attenuated H2 Pandemic Influenza Vaccine Candidates in Mice and Ferrets (2013) (20)
- Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. (2013) (19)
- Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evolution (2020) (18)
- SARS-CoV-2: A New Song Recalls an Old Melody (2020) (18)
- Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus (2014) (17)
- Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19 (2020) (16)
- Antigen-activated dendritic cells ameliorate influenza A infections. (2013) (16)
- Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK (2006) (16)
- Vaccines for older adults (2021) (15)
- Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection (2020) (15)
- Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance (2021) (15)
- Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates. (2012) (14)
- Evolution of immunity to SARS-CoV-2 (2020) (14)
- Convalescent plasma treatment for COVID‐19: Tempering expectations with the influenza experience (2020) (14)
- Safety Evaluation in Chickens of Candidate Human Vaccines Against Potential Pandemic Strains of Influenza (2003) (14)
- Persistence of SARS-CoV-2–Specific IgG in Children 6 Months After Infection, Australia (2021) (14)
- Science, not speculation, is essential to determine how SARS-CoV-2 reached humans (2021) (13)
- Molecular clamp stabilised Spike protein for protection against SARS-CoV-2 (2020) (13)
- A Live Attenuated Equine H3N8 Influenza Vaccine Is Highly Immunogenic and Efficacious in Mice and Ferrets (2014) (13)
- Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers (2020) (13)
- Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine (2018) (13)
- COVID-19 vaccines: time to talk about the uncertainties (2020) (13)
- DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice (2002) (13)
- Generation and Characterization of an H9N2 Cold-Adapted Reassortant as a Vaccine Candidate (2003) (12)
- Respiratory Virus Vaccines (2015) (11)
- Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort (2021) (11)
- A Tale of Two Mutations: Beginning to Understand the Problems with Egg-Based Influenza Vaccines? (2019) (11)
- The Temperature-Sensitive and Attenuation Phenotypes Conferred by Mutations in the Influenza Virus PB2, PB1, and NP Genes Are Influenced by the Species of Origin of the PB2 Gene in Reassortant Viruses Derived from Influenza A/California/07/2009 and A/WSN/33 Viruses (2014) (11)
- Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model. (2018) (11)
- Evaluation of the Biological Properties and Cross-Reactive Antibody Response to H10 Influenza Viruses in Ferrets (2017) (11)
- Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018 (2020) (11)
- The Critical Interspecies Transmission Barrier at the Animal–Human Interface (2019) (11)
- Human infections with avian influenza viruses. (2005) (10)
- Memory CD4+ T cells: beyond "helper" functions. (2012) (10)
- How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines (2019) (10)
- Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses (2017) (9)
- The Role of Animal Models In Influenza Vaccine Research (2010) (9)
- Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope? (2017) (9)
- Refining the approach to vaccines against influenza A viruses with pandemic potential. (2015) (9)
- A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets (2015) (8)
- Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. (2019) (8)
- Live Attenuated Cold-Adapted Influenza Vaccines. (2020) (7)
- Passive immunization with influenza haemagglutinin specific monoclonal antibodies (2018) (7)
- Influenza vaccination and prevention of cardiovascular disease mortality – Authors' reply (2018) (7)
- Correlates of protection, thresholds of protection, and immunobridging in SARS-CoV-2 infection (2022) (7)
- Roadblocks to translational challenges on viral pathogenesis (2013) (7)
- Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay (2021) (7)
- Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection (2023) (7)
- Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children? (2022) (6)
- H 5 N 1 Viruses and Vaccines (2007) (6)
- Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates. (2015) (6)
- (SARS-CoV) Pulmonary Infection of Mice Acute Respiratory Syndrome-Coronavirus Mechanisms of Host Defense following Severe (2004) (5)
- Preclinical and clinical developments for combination treatment of influenza (2022) (5)
- Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses (2022) (5)
- Epidemiological Data on the Effectiveness of Influenza Vaccine-Another Piece of the Puzzle. (2018) (5)
- Reduced seroconversion in children compared to adults with mild COVID-19 (2021) (5)
- Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids (2021) (5)
- Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection (2021) (5)
- Influenza a infections: from chickens to humans (2001) (5)
- Virology under the Microscope—a Call for Rational Discourse (2023) (4)
- ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsies (2022) (4)
- H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets. (2018) (4)
- Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection (2021) (4)
- A SURVEY OF DISTRIBUTED FAULT TOLERANCE STRATEGIES (2013) (4)
- Rapid communications Detection of adamantane-sensitive influenza A ( H 3 N 2 ) viruses in Australia , 2017 : a cause for hope ? (2017) (4)
- A randomised trial of two 2-dose influenza vaccination strategies for patients following autologous haematopoietic stem cell transplantation. (2020) (4)
- Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19 (2022) (4)
- Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model (2022) (4)
- Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia (2021) (3)
- Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical) (2020) (3)
- Abstracts: NAPCON (2019) (3)
- Induction of protective immunity against influenza A/Jiangxi-Donghu/346/2013 (H10N8) in mice. (2017) (3)
- Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise (2022) (3)
- The challenge of flu transmission (2012) (3)
- 18 – Influenza vaccine—live (2013) (2)
- Detection of influenza in managed quarantine in Australia and the estimated risk of importation (2022) (2)
- Advances in Influenza Virus Research: A Personal Perspective (2018) (2)
- Evaluation of six commercial SARS-CoV-2 Enzyme-Linked Immunosorbent assays for clinical testing and serosurveillance (2021) (2)
- The 2018 annual cost burden for children under five years of age hospitalised with respiratory syncytial virus in Australia. (2022) (2)
- A case report describing the immune response of an infant with congenital heart disease and severe COVID-19 (2021) (2)
- First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2 (2021) (2)
- The role of animal models in influenza vaccine research (2008) (2)
- GROWTH RATES OF DRY PARTICULATE FOULING UNDER VARIABLE PROCESS CONDITIONS (2011) (2)
- Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques (2020) (2)
- Correction: Influenza A Virus Assembly Intermediates Fuse in the Cytoplasm (2016) (2)
- The Pandemic Threat of Avian Influenza Viruses (2006) (2)
- Live Attenuated Influenza Vaccines for Pandemic Preparedness. (2020) (1)
- Temporal differences in culturable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) from the respiratory and gastrointestinal tracts in a patient with moderate coronavirus disease 2019 (COVID-19) (2021) (1)
- Temporal differences in culturable SARS-CoV-2 from the respiratory and gastro-intestinal tracts in a patient with moderate COVID-19. (2021) (1)
- Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids (2022) (1)
- Rapid Application of the Molecular Clamp Platform for SARS-CoV-2 (2020) (1)
- Molecular Structures of Native HA Trimers on 2009 H1N1 Pandemic Influenza Virus Complexed with Neutralizing Antibodies (2013) (1)
- Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine (2022) (1)
- Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2 (2022) (1)
- Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2 (2022) (1)
- Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021. (2020) (1)
- Macrophages only sense infectious SARS-CoV-2 when they express sufficient ACE2 to permit viral entry, where rapid cytokine responses then limit viral replication (2023) (1)
- A new route to vaccines using PROTACs (2022) (1)
- Virology under the Microscope—a Call for Rational Discourse (2023) (1)
- A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories. (2021) (1)
- Immune Responses in an Infant with Congenital Heart Disease and Severe COVID-19 (2021) (1)
- Immune responses to SARS-CoV-2 in children of parents with symptomatic COVID-19 (2020) (1)
- Development of Effective Vaccines Commentary against Pandemic Influenza (2006) (1)
- Evaluation of novel influenza A viruses and their pandemic potential. (2000) (1)
- Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months (2022) (1)
- Molecular epidemiology of influenza virus isolated in Brazil from 1996 to 2000 (2004) (1)
- Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 (2021) (1)
- The threat of zoonotic coronaviruses (2021) (1)
- Parallel use of pluripotent human stem cell lung and heart models provide new insights for treatment of SARS-CoV-2 (2022) (1)
- Correction for Moore et al., Severity of Clinical Disease and Pathology in Ferrets Experimentally Infected with Influenza Viruses Is Influenced by Inoculum Volume (2015) (1)
- Fibrin clot characteristics and anticoagulant response in a SARS‐CoV‐2‐infected endothelial model (2022) (1)
- Vaccination with DNA encoding conserved influenza viral proteins (2001) (1)
- Virology under the Microscope—a Call for Rational Discourse (2023) (1)
- KS4-1 Pandemic influenza: Lessons from 2009 and future challenges (2013) (0)
- Book reviews (2019) (0)
- The PB2 Subunit of the Influenza Virus RNA Polymerase Affects Virulence by Interacting with the Mitochondrial Antiviral Signaling Protein and Inhibiting Expression of Beta Interferon (cid:1) (2010) (0)
- Sequential Transmission of Influenza Viruses in Ferrets Does Not Enhance Infectivity and Does Not Predict Transmissibility in Humans (2022) (0)
- Bromodomain Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV2 Infection (2020) (0)
- High-Af fi nity H 7 Head and Stalk Domain – Speci fi c Antibody Responses to an Inactivated In fl uenza H 7 N 7 Vaccine After Priming With Live Attenuated In fl uenza Vaccine (2015) (0)
- Macrophage ACE2 is necessary for SARS-CoV-2 replication and subsequent cytokine responses that restrict continued virion release (2023) (0)
- Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2 (2023) (0)
- Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants (2023) (0)
- Evaluation of Replication and Cross-Reactive Antibody Responses of H2 Subtype Influenza Viruses in Mice and Ferrets (cid:1) (2010) (0)
- An iTSC-derived placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility in syncytiotrophoblasts (2021) (0)
- When to update COVID-19 vaccine composition (2023) (0)
- Variants of the hemagglutinin and neuraminidase of influenza (2005) (0)
- Faculty Opinions recommendation of Microbiota regulates immune defense against respiratory tract influenza A virus infection. (2011) (0)
- An addition to treatment options for avian influenza A H5N1? (2015) (0)
- Infectious Diseases, National Institute of Allergy and Infectious (2014) (0)
- Generation of candidate H5N1 and H9N2 influenza vaccines for pandemic preparedness (2001) (0)
- SIAN OURNAL OF HEMISTRY (2018) (0)
- Robust and prototypical immune responses towards COVID-19 BNT162b2 vaccines in Indigenous people (2022) (0)
- Crystal Structure of a Complex formed between FLD194 Fab and Transmissible Mutant H5 Haemagglutinin (2015) (0)
- Echinococcosis, Ningxia, China (2019) (0)
- New options to treat influenza B (2017) (0)
- S0950268821000315jra 1..8 (2021) (0)
- Genomic Analysis Reveals Age-Dependent Innate Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (cid:1) † (2008) (0)
- Nonhuman primate models for evaluation of SARS-CoV-2 vaccines (2022) (0)
- Ferrets and Pigs Induced by a Single-Cycle Comparison of Heterosubtypic Protection in (2018) (0)
- Vesicular Stomatitis Virus-Based H5N1 Avian Influenza Vaccines Induce Potent Cross-Clade Neutralizing Antibodies in Rhesus Macaques (cid:1) (2011) (0)
- Faculty Opinions recommendation of Rapid generation of a mouse model for Middle East respiratory syndrome. (2014) (0)
- Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 (2020) (0)
- Vaccines Discovery and Development (2011) (0)
- The Influenza Imperative: An Urgent Need to Leverage Lessons from COVID-19 to Prepare for a Global Response to Seasonal and Pandemic Influenza. (2022) (0)
- Development and evaluation of candidate influenza a vaccines for pandemic preparedness (2004) (0)
- Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines (2017) (0)
- Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and γδ T cell perturbations (2023) (0)
- New options to treat influenza B (2017) (0)
- Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets (cid:1) (2008) (0)
- Protective neutralization titre for COVID-19 (2021) (0)
- Faculty Opinions recommendation of Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway. (2008) (0)
- Induction of protective immunity against influenza A / Jiangxi-Donghu / 346 / 2013 ( H 10 N 8 ) in mice (2017) (0)
- Integrated immune networks in SARS-CoV-2 infected pregnant women reveal differential NK cell and unconventional T cell activation (2021) (0)
- Emerging Novel Influenza Viruses with Pandemic Potential. (2018) (0)
- IJSRD-International Journal for Scientific Research & Development| Vol. 3, Issue 06, 2015 | ISSN (online): 2321-0613 (2015) (0)
- Subbarao and Vaccine Strategies Emerging Respiratory Viruses : Challenges (2006) (0)
- E. De Clerq, ‘Novel compounds in preclinical/early clinical development for the treatment of HIV infections’. Reviews in Medical Virology 10(4) 2000, 255–277 (2000) (0)
- Highly Sensitive Simultaneous Determination of Oxybutynin and N- Desethyloxybutynin in Human Plasma by LC-MS/MS (2016) (0)
- Hepatocyte Growth Factor / Scatter Factor-Met Signaling Induces Proliferation , Migration , and Morphogenesis of Pancreatic Oval Cells 1 (2005) (0)
- What influenza activity can we anticipate in 2022? (2022) (0)
- The re-emergence of influenza following the COVID-19 pandemic in Victoria, Australia (2023) (0)
- PULCHERRIMUS IN MALARIA TRANSMISSION IN GHASSREGHAND ( BALUCHISTAN ) , IRAN 1 (2004) (0)
- Author index (2012) (0)
- Corrigendum to: “Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets” [Virology 446 (1–2) (2013) 349–356] (2015) (0)
- Respiratory viruses: New frontiers—a Keystone Symposia report (2023) (0)
- Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells (2023) (0)
- Rapid Generation of Attenuated Vaccines (2004) (0)
- Efficacy of a patient isolation hood in reducing exposure to airborne infectious virus in a simulated healthcare setting (2022) (0)
- SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice (2022) (0)
- Antigen-activated dendritic cells ameliorate influenza A infections. (2020) (0)
- Heparin Inhibits SARS-CoV-2 Replication in Human Nasal Epithelial Cells (2022) (0)
- Infants Harness the Germline against RSV. (2018) (0)
- M ay 2 00 1 Composite Quasar Spectra From the Sloan Digital Sky Survey 1 (2001) (0)
- The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death (cid:1) ‡ (2009) (0)
- Immunization with trimeric S glycoprotein protects from SARS-CoV challenge despite the presence of in vitro facilitating antibodies (2005) (0)
- The Development of Live-Attenuated Vaccines for Pandemic Influenza (2010) (0)
This paper list is powered by the following services:
Other Resources About Kanta Subbarao
What Schools Are Affiliated With Kanta Subbarao?
Kanta Subbarao is affiliated with the following schools:
